Calendario›LYEL›START

START

A Biomarker Screening Protocol for Participants With Solid Tumors

Ensayo de Lyell Immunopharma, Inc. en Triple Negative Breast Cancer · Non-small Cell Lung Cancer · Non Small Cell Lung Cancer · Non Small Cell Lung Cancer Metastatic · Non-Small Cell Carcinoma of Lung, TNM Stage 4 · Advanced Breast Cancer · Advanced Lung Carcinoma · NSCLC · NSCLC, Recurrent · NSCLC Stage IV · Relapsed Cancer · Relapse/Recurrence · Recurrent Breast Cancer · Recurrent NSCLC · Platinum-resistant Ovarian Cancer · Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Cancer · Endometrial Cancer · Endometrioid Tumor · High Grade Serous Carcinoma · Ovarian Epithelial Cancer (del registro, en inglés).

Más ensayos de: Cáncer de mama triple negativo · Cáncer de pulmón no microcítico · Cáncer de mama avanzado · Cáncer de ovario resistente al platino · Cáncer de ovario · Carcinoma peritoneal primario · Cáncer de trompa de Falopio · Cáncer de endometrio.

Fase

no aplica

Estado

Interrumpido

Participantes

10

previstos

Centros

1

Fin del objetivo primario

feb 2025

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en may 2023.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Pipeline Reprioritization».

Qué mide

To identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials (del registro, en inglés) (5 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroBiomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.

Más ensayos de LYEL

Todos los de LYEL, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05891197), actualizada en jun 2025.